Sepsis Clinical Trial
Official title:
Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock
Septic shock is a major cause of mortality and morbidity in critically ill patients. Septic
Shock is associated with an overwhelming, systemic overflow of pro inflammatory and
anti-inflammatory mediators, which leads to generalized endothelial damage, multiple organ
failure, and altered cellular immunological responsiveness. Although our understanding of
the complex pathophysiological alterations that occur in septic shock has increased greatly
as a result of recent clinical and preclinical studies, mortality associated with the
disorder remains unacceptably high, ranging from 30% to 50%. To date, attempts to improve
survival with innovative, predominantly anti-inflammatory therapeutic strategies have been
disappointing. A standard hemofiltration rate of 35 ml/kg/hour has been successfully used to
treat acute renal failure. However, this dose does not alter plasma levels of inflammatory
mediators, suggesting that its ability to clear these mediators is suboptimal. Higher doses
of hemofiltration (up to 120 ml/kg per hour) have been demonstrated to improve cardiac
function and hemodynamics in several animal models of sepsis. High-volume hemofiltration
(HVHF) was thus conceived and applied in patients with septic shock, showing an improvements
in hemodynamics with decreased vasopressor requirements and improved survival in patients
admitted after a cardiac arrest.
The main benefit described with high volume hemofiltration is a hemodynamic improvement (e.g
reduction in catecholamines' requirement). This improvement seems to be due to the removal
of a badly defined network of middle molecular weight peptides. To remove efficiently these
middle molecular peptides, a high filtration rate is needed. However, with high filtration
rates, there is also a high clearance for smaller molecules, including antibiotics,
electrolytes, vitamins, trace elements and amino acids.
The cascade hemofiltration system has been designed for a more efficient removal of middle
molecular weight peptides with a limited solute consumption.
The goal of this study is the evaluation of the hemodynamic improvement using cascade
hemofiltration in patients treated for septic shock.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
| Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
| Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
| Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
| Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
| Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
| Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
| Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
| Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
| Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
| Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
| Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
| Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
| Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
| Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
| Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
| Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
| Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
| Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
| Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |